Small Molecular Inhibitor of Transforming Growth Factor-β Protects Against Development of Radiation-Induced Lung Injury. In Regard to Anscher MS et al. (Int J Radiat Oncol Biol Phys 2008;71:1-9).

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 2, 2008, Pages 630-

  Bahl, Amit ^a   Sharma, Daya N ^a   Rath, Gaura K ^a   Julka, Pramod K ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; BROMELAIN; CHYMOTRYPSIN; MESSENGER RNA; PAPAIN; PROTEIN INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; SM 16; TRANSFORMING GROWTH FACTOR BETA; TRYPSIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER RADIOTHERAPY; DISEASE COURSE; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; LETTER; LUNG CANCER; LUNG FIBROSIS; MEDICAL DOCUMENTATION; MORBIDITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BINDING; PROTEIN SYNTHESIS; UTERINE CERVIX CANCER;

AZABICYCLO COMPOUNDS; LUNG; PEPTIDE HYDROLASES; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; TRANSFORMING GROWTH FACTOR BETA;

EID: 51449094043     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.05.057     Document Type: Letter

References (10)

1. Anscher M.S., Thrasher B., Zgonjanin L., et al. Small molecular inhibitor of transforming growth factor-β protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 71 (2008) 1-9
2. Desser L., Holomanova D., Zavadova E., et al. Oral therapy with proteolytic enzymes decreases excessive TGF-β levels in human blood. Cancer Chemother Pharmacol 47 Suppl. (2001) S10-S15
3. Desser L., Herbacek I., Zavadova E., et al. Conversion of α2 macroglobulin to the fast-form by Wobenzym interrupts the autocrine loop of TGFβ production in melanoma cells. Proc Am Assoc Cancer Res 40 (1999) 525
4. Hall S.W., LaMarre J., Marshall L.B., et al. Binding of transforming growth factor β-1 to methylamine modified α2 macroglobulin and to binary and ternary α2 macroglobulin-proteinase complexes. Biochem J 281 (1992) 569-575
5. Desser L., Sakalova A., Zavadova E., et al. Concentrations of soluble tumor necrosis factor receptors, beta 2-microglobulin, IL-6 and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme-chemotherapy. Int J Immunother 13 (1997) 121-130
6. Lauer D., Muller R., Cott C., et al. Modulation of growth factor binding properties of α2-macroglobulin by enzyme therapy. Cancer Chemother Pharmacol 47 Suppl. (2001) S4-S9
7. Gujral S., Patnaik P.M., Kaul R., et al. Efficacy of hydrolytic enzymes in preventing radiation therapy induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol 47 Suppl. (2001) S23-S28
8. Dale P.S., Tamhankar C.P., George D., et al. Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: Evidence of the reduction of acute side effects. Cancer Chemother Pharmacol 47 Suppl. (2001) S29-S34
9. Beuth J., Ost B., Pakdaman A., et al. Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients-Results of an epidemiological multicentre retrolective cohort study. Cancer Chemother Pharmacol 47 Suppl. (2001) S45-S54
10. Bahl A., Chander S., Julka P.K., et al. Micronuclei evaluation of reduction in neoadjuvant chemotherapy related acute toxicity in locally advanced lung cancer: An Indian experience. J Assoc Phys Ind 54 (2006) 191-195